LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB.
LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB.
复制标题
LECT2，慢性乙型肝炎患者肝纤维化的新型直接生物标志物
DOI：
10.3389/fmolb.2021.749648
复制
发表时间：
2021
影响因子：
5
通讯作者：
Gao Y
中科院分区：
文献类型：
--
作者：
Xu H;Li X;Wu Z;Zhao L;Shen J;Liu J;Qin J;Shen Y;Ke J;Wei Y;Li J;Gao Y
慢性B型肝炎（CH B）患者合并严重肝纤维化更有可能进展为较差的预后。一旦肝纤维化达到显著肝纤维化（≥S2），则考虑治疗。白细胞来源的趋化因子-2（LECT 2）已被证明有助于肝纤维化进展。没有研究集中在LECT 2在CHB患者肝纤维化中的作用。本研究共纳入227例慢性乙型肝炎患者，分为训练组（n = 147）和验证组（n = 80）。检测LECT 2在血清、肝组织蛋白和mRNA中的表达，分析LECT 2与肝纤维化的可能关系。采用受试者工作特征曲线（ROC）评估LECT 2预测肝纤维化的有效性。数据显示，LECT 2与肝纤维化的进展呈正相关。在训练组中，LECT 2被证明具有比APRI和FIB-4更好的有效性。显著肝纤维化的AUC为0.861、0.698和0.734，晚期肝纤维化的AUC为0.855、0.769和0.752。此外，LECT 2在不同状态的CHB患者中的疗效也得到了检查，LECT 2的有效性也在验证组中得到了证实。所有结果证实LECT 2可以作为一个完美的预测器，从而提供了一种新的和直接的生物标志物，以更准确地估计肝纤维化。
Chronic hepatitis B (CHB) patients with severe liver fibrosis would be more likely to progress to a poorer prognosis. Treatment is considered once the liver fibrosis reaches significant liver fibrosis (≥S2). Leukocyte cell-derived chemotaxin-2 (LECT2) has been shown to contribute to liver fibrosis progression. No research has focused on the role of LECT2 in liver fibrosis in CHB patients. This study enrolled 227 CHB patients and divided them into the training group (n = 147) and validation group (n = 80), respectively. The expression of LECT2 in serum, protein and mRNA of the human liver tissues was detected to analyze the possible associations between LECT2 and liver fibrosis. A receiver operating characteristic curve (ROC) was used to estimate the efficacy of LECT2 for predicting liver fibrosis. The data showed that there was a positive relationship between LECT2 and the progression of liver fibrosis. In the training group, LECT2 was demonstrated to have better effectiveness than APRI and FIB-4. The AUC was 0.861, 0.698, and 0.734 for significant liver fibrosis, and 0.855, 0.769, and 0.752 for advanced liver fibrosis. Besides, the efficacy of LECT2 in different statuses of patients with CHB was examined and the effectiveness of LECT2 had also been confirmed in the validation group. All the results confirmed that LECT2 could act as a perfect predictor and thus offers a novel and direct biomarker to estimate liver fibrosis more accurately.
登录
查看更多内容
影响因子：
13.5
作者：
L'Hermitte, Antoine;Pham, Sandrine;Couty, Jean-Pierre
通讯作者：
Couty, Jean-Pierre
影响因子：
13.5
作者：
Chen, Chi-Kuan;Yang, Ching-Yao;Kuo, Min-Liang
通讯作者：
Kuo, Min-Liang
影响因子：
29.4
作者：
MCGILL, DB;RAKELA, J;OTT, BJ
通讯作者：
OTT, BJ
影响因子：
6.4
作者：
Ong, H. T.;Tan, P. K.;Hui, K. M.
通讯作者：
Hui, K. M.
影响因子：
5
作者：
Cao, Qi;Lu, Xin;Dilsizian, Vasken
通讯作者：
Dilsizian, Vasken